UCSF study shows that drug administered during heart procedures preserves blood flow into the heart muscle

November 13, 2000

A drug commonly used during invasive heart procedures not only helps maintain blood flow through the large blood vessels that have been enlarged during the procedure by balloons and metal tubes, but also preserves blood flow through the smaller blood vessels downstream that may become blocked by debris. This helps to restore much needed oxygen supply directly to heart muscle, according to C. Michael Gibson, MD, UCSF chief of interventional cardiology, director of the Core Angiographic Laboratory at UCSF and lead author of the study.

Gibson presented the results at the American Heart Association in New Orleans, Louisiana, on Sunday, November 12.

"During invasive heart procedures many small blood clots may be released during the placement of a tube or stent in the artery, and these small clots may in turn float downstream and block the small vessels or capillaries that supply blood to the heart muscle itself. In order to prevent irreversible injury to the heart that can occur following stenting, it is critical that this complex network of very small blood vessels that supply oxygen to the heart muscle remain intact," explained Gibson. "Our study clearly demonstrates that use of the drug eptifibatide at the time of stent placement helps preserve the integrity of the microvasculature and blood flow into the heart muscle."

Eptifibatide (Integrilin®) blocks the receptors on platelets, components in the blood that are responsible for coagulation. This reduces clot formation that can lead to heart attack or death, said Gibson. Use of eptifibatide significantly improved the ability of the heart to speed up its blood flow in large arteries by 39 percent when compared with placebo. It improved the speed at which blood entered the microvasculature in the heart muscle by 84 percent compared to placebo, explained Gibson. Improving the entry of blood into the heart muscle preserves blood supply to the previously oxygen-starved heart muscle in patients undergoing angioplasty, he said.

Nearly 600,000 angioplasty procedures are performed in the United States each year. The procedure is used to stretch the walls of narrowed blood vessels in the heart that limit the supply of oxygen to heart muscle. More than six out of ten procedures involve the placement of intracoronary stents, metal mesh structures that hold the heart arteries open after the procedure. Although angioplasty and intracoronary stenting are generally successful at restoring blood flow and preventing the collapse of the artery, the use of a stent into the artery wall can result in the clumping of platelets and the development of blood clots. A clot can obstruct blood flow through both large and small arteries.

Investigators evaluated angiograms of 65 patients taken before and after stent placement to determine the extent of and speed of blood flow through the network of very small blood vessels that supply oxygen to the heart muscle. With computer assisted analysis, investigators were able to measure how bright the heart muscle became (due to a surge of dye indicating increased blood flow to the microvasculature) after use of the eptifibatide.
Co-investigators in the study were David Cohen, MD, assistant professor of medicine, Harvard University and James E. Tcheng, MD, associate professor of medicine, Duke University.

Integrilinâ was developed and is marketed in the United States by COR Therapeutics, Inc., South San Francisco and Key Pharmaceuticals, Inc., Kenilworth, New Jersey. Both companies funded the study.

University of California - San Francisco

Related Angioplasty Articles from Brightsurf:

Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty
A new study found the rate of heart attack and severe complications before, during or soon after elective surgery to open a blocked artery was similar between patients treated with clopidogrel and those who received the more potent antiplatelet medication ticagrelor.

Study finds significant variability in doctors' angioplasty death rates
Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI); however, doctors should not be judged solely on the rate of patients who die from the procedure.

Beta-blockers following angioplasty show little benefit for some older patients
Following coronary angioplasty, beta-blockers did not significantly improve mortality rates or reduce the number of future cardiovascular incidents for older patients with stable angina but no history of heart attack or heart failure, according to a study published today in the JACC: Cardiovascular Interventions.

Sleep disorders may predict heart events after angioplasty
People who have had procedures to open blocked heart arteries after acute coronary syndrome (ACS) may have a higher risk of death, heart failure, heart attack and stroke if they have sleep disorders, such as sleep apnea, compared to those who don't.

Reasons for hospital-level variations in bleeding post-angioplasty are unclear
The use of bleeding avoidance strategies has only a modest effect on the variation in bleeding rates post-angioplasty among hospitals performing this procedure, leaving about 70 percent of the causes for this variation unexplained, according to a study published today in JACC: Cardiovascular Interventions.

US prediction models for kidney injury following angioplasty hold up in Japan
Models developed by the American College of Cardiology NCDR CathPCI Registry to predict the likelihood of angioplasty patients developing acute kidney injury and acute kidney injury requiring dialysis have proven to be effective among patients in Japan.

IV beta blockers before angioplasty are safe, but offer no clinical benefit
Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack -- ST-segment elevation myocardial infarction (STEMI) -- was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

Life-threatening bowel ischemia can often be treated by balloon angioplasty
Acute mesenteric ischemia (AMI) can be successfully treated with endovascular therapy such as balloon angioplasty, according to research from the University of Eastern Finland.

Radial access used less than femoral approach for emergency angioplasty
Although using the radial artery as the access point for angioplasty has been linked to reduced bleeding compared to use of the femoral artery, only a small number of high-risk heart attack patients who undergo rescue angioplasty -- emergency procedures following failed therapy with clot-busting drugs -- are treated by radial access, according to a study published today in the Journal of the American College of Cardiology: Cardiovascular Interventions.

Use of rarely appropriate angioplasty procedures declined sharply
The number of angioplasty procedures classified as rarely appropriate declined sharply between 2010 and 2014, as did the number of those performed on patients with non-acute conditions, according to a study published today in the Journal of the American Medical Association and simultaneously presented at a meeting of the American Heart Association in Orlando.

Read More: Angioplasty News and Angioplasty Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.